Our Pipeline

NRS-033

Our most advanced product candidate NRS-033 is a 2^nd generation long-acting injectable opioid antagonist entering a Phase 2 trial. NRS-033 is intended to overcome the key efficacy-limiting problems of retention, therapeutic strength, safety, and accessibility of the 1^st generation once-monthly long acting injectable opioid antagonists extended release naltrexone (XR-NTX). NRS-033 may also have utility in other diseases of compulsion and addiction, such as gambling, trichotillomania, binge eating, and cannabis use disorder.

The development of NRS-033 for OUD is supported in part by two National Institutes of Health (NIH) grants funding totaling over $30mm (HEAL Initiative Awards UH3DAA048234, granted in 2019 and 1U01DA061643 granted in 2024, respectively.)